As of May 22, 2025, Endomines AB (publ) has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $51.80, this represents a potential upside of -1463218.3%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -116510824134822000.0% |
| Potential Upside (10-year) | -1463218.3% |
| Discount Rate (WACC) | 4.8% - 5.8% |
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2021 | 0 | 100% |
| 12-2022 | 204 | 850561% |
| 12-2023 | 547 | 168% |
| 12-2024 | 1048826 | 191670% |
| 12-2025 | 1629399355 | 155255% |
| 12-2026 | 2278382274014 | 139730% |
| 12-2027 | 2867500718667999 | 125757% |
| 12-2028 | 3248349642365200896 | 113182% |
| 12-2029 | 3312173403231435096064 | 101865% |
| 12-2030 | 3039868937952589000998912 | 91679% |
| 12-2031 | 2511242223630179757486768128 | 82510% |
Net profit margin is expected to improve from -1088029% in 12-2021 to -1074618% by 12-2031, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2021 | (261) | -1088029% |
| 12-2022 | (2,215,135) | -1085007% |
| 12-2023 | (5,921,491) | -1082702% |
| 12-2024 | (11,332,707,058) | -1080513% |
| 12-2025 | (17,571,986,211,925) | -1078433% |
| 12-2026 | (24,525,818,450,292,408) | -1076458% |
| 12-2027 | (30,856,663,937,010,356,224) | -1076082% |
| 12-2028 | (34,942,838,928,212,716,683,264) | -1075711% |
| 12-2029 | (35,617,211,368,608,126,979,801,088) | -1075343% |
| 12-2030 | (32,677,932,733,556,840,188,281,356,288) | -1074978% |
| 12-2031 | (26,986,254,301,007,868,147,210,727,194,624) | -1074618% |
with a 5-year average of $55 million. Projected CapEx is expected to maintain at approximately 41995% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2022 | 17199 |
| 12-2023 | 63115 |
| 12-2024 | 88153916 |
| 12-2025 | 136941231933 |
| 12-2026 | 191498025415315 |
| 12-2027 | 241032577540171008 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 3,127 |
| Days Inventory | 124 |
| Days Payables | 718 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 6M/2022 | (1,074,311) | (608) | 42868 | (75,737) | (1,040,834) |
| 2023 | (5,726,263) | (3,249) | 229678 | (242,315) | (5,710,378) |
| 2024 | (10,991,185,756) | (6,217,147) | 440454087 | (684,417,586) | (10,741,005,110) |
| 2025 | (17,041,408,667,864) | (9,640,028,197) | 684265390113 | (1,033,021,360,714) | (16,683,012,669,067) |
| 2026 | (23,783,875,727,089,356) | (13,454,915,030,841) | 956805420916960 | (1,370,257,936,189,717) | (23,356,968,296,785,760) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -116510824134822000.0% |
| 10-Year DCF (Growth) | 0.00 | -1463218.3% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Endomines AB (publ) (ENDO.ST) a buy or a sell? Endomines AB (publ) is definitely a sell. Based on our DCF analysis, Endomines AB (publ) (ENDO.ST) appears to be overvalued with upside potential of -1463218.3%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $51.80.